drugset / Trial / NCT07426484
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Phase 4
Not yet recruiting
80 enrolled
Dana-Farber Cancer Institute
Checkpoint Therapeutics, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC). The name of the drug involved in this research study is: -cosibelimab (a type of an anti-PD-L1 antibody)
Timeline
- Start
- 2026-07
- Primary completion
- 2030-12-15
- Completion
- 2032-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cosibelimab | Monoclonal antibody | — | Intravenous |
| Background | Everolimus | Small molecule | — | — |
| Background | Prednisone | Other / unclassified | — | — |
| Background | Sirolimus | Small molecule | — | — |